InsiderTrades

Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2025-05-05 00:00:00 ET · period of report 2025-05-01 · accession 0000875320-25-000190 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-05-05 2025-05-01 VRTX Upadhyay Suketu Dir A - Grant $0.00 +796 3,355 +31% $0
D 2025-05-05 2025-05-01 VRTX Upadhyay Suketu Dir D - Sale to Iss — -1,001 2,354 -30% —
D 2025-05-05 2025-05-01 VRTX Upadhyay Suketu Dir A - Grant — +1,001 2,476 +68% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2025-05-01 A A 796 $0.00 3,355 D — — (F1) Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.
2 Common Common Stock 2025-05-01 D D 1,001 — 2,354 D — — (F2) Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2024, Mr. Upadhyay deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units.
3 Derivative Deferred Stock Units 2025-05-01 A A 1,001 — 2,475.60 D — · — to — 1,001 Common Stock (F2) Upon the vesting of restricted stock units granted to Mr. Upadhyay on May 1, 2024, Mr. Upadhyay deferred the receipt of 1,001 shares of common stock and received instead 1,001 deferred stock units pursuant to our deferred compensation plan. As a result, Mr. Upadhyay is reporting the disposition of 1,001 shares of common stock in exchange for an equal number of deferred stock units. (F3) Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Upadhyay's service on our board of directors, (ii) a change of control of our company and (iii) Mr. Upadhyay's disability or death.